Prevalence and Patterns of Omeprazole and H2 Blocker Use in Neonates in a Neonatal Intensive Care Unit Setting: Omeprazole and H2 Blockers in Neonates

Shahid Iqbal; Irum Javed; Muhammad Abdul Quddus; Rukhsana Munawar

doi:10.54393/pjhs.v5i10.1859

Authors

Shahid Iqbal Department of Pediatric Medicine, Poonch Medical College, Rawalakot, Pakistan
Irum Javed Department of Pediatric Medicine, Poonch Medical College, Rawalakot, Pakistan
Muhammad Abdul Quddus Department of Gastroenterology, Poonch Medical College, Rawalakot, Pakistan
Rukhsana Munawar Department of Pharmacology, Poonch Medical College, Rawalakot, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i10.1859

Keywords:

Stress Ulceration, Gastroesophageal Reflux, Proton Pump Inhibitors, H2 Blockers

Abstract

H2 blockers and omeprazole therapy have not been shown to improve clinical symptoms associated with stress ulceration in newborn trials. There were concerns regarding the reliability and efficacy of treating stress ulcers in adults and children with omeprazole and H2 blockers. Objective: To investigate the prevalence and patterns of H2 blocker and omeprazole use in neonates, assess their efficacy, and evaluate potential risks associated with their use. Methods: Sick infants admitted to NICUs within the Department of Pediatrics ‘Sheikh Khalifa Bin Zaid Al Nahyan Hospital’, Rawalakot, Azad Kashmir were included in this retrospective study. Data collection was done from the hospital records from January 2022 to December 2022. All NICU infants who were at least 28 days old, were critically sick participated in this investigation. Results: There was a twice as high frequency of omeprazole use as of H2 blocker use. More frequently used drugs were Omeprazole and Cimetidine. That was from January to December in the year 2023 Omeprazole group rose from 3. 1% to 3. 8% and the H2 blocker group rose from 1. 3% to 1. 9%. Conclusions: Hospitalized neonates including those without GIT issues were commonly exposed to prescriptions of H2 blockers end Omeprazole. The findings depicted the need for controlling and effectively utilizing omeprazole and H2 blockers. Hence there was a need for more research in relation to the safety and efficacy of omeprazole and H2 blockers in infants.

References

Tan J, Jeffries S, Carr R. A review of histamine-2 receptor antagonist and proton pump inhibitor therapy for gastroesophageal reflux disease in neonates and infants. Pediatric Drugs. 2023 Sep; 25(5): 557-76. doi: 10.1007/s40272-023-00580-z.

Panula P. Histamine receptors, agonists, and antagonists in health and disease. Handbook of Clinical Neurology. 2021 Jan; 180: 377-87. doi: 10.1016/B978-0-12-820107-7.00023-9.

Størdal K, Ma A, Beck CE. Reducing the use of proton pump inhibitors in infants with reflux symptoms. British Medical Journal. 2024 May; 385. doi: 10.1136/bmj-2022-074588.

Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapies. 2021 Jan; 76(1): 13-21. doi: 10.1016/j.therap.2020.06.019.

Shanika LG, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. European Journal of Clinical Pharmacology. 2023 Sep; 79(9): 1159-72. doi: 10.1007/s00228-023-03534-z.

Zhang W, Zhang Q, Cao Z, Zheng L, Hu W. Physiologically based pharmacokinetic modeling in neonates: Current status and future perspectives. Pharmaceutics. 2023 Dec; 15(12): 2765. doi: 10.3390/pharmaceutics15122765.

Benninga MA, Broekaert IJ, Gottrand F, Papadopoulou A, Ribes-Koninckx C, Thomson M et al. Drugs in focus: proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition. 2021 May; 72(5): 645-53. doi: 10.1097/MPG.0000000000003063.

Jadcherla SR, Hasenstab KA, Wei L, Osborn EK, Viswanathan S, Gulati IK et al. Role of feeding strategy bundle with acid-suppressive therapy in infants with esophageal acid reflux exposure: a randomized controlled trial. Pediatric Research. 2021 Feb; 89(3): 645-52. doi: 10.1038/s41390-020-0932-4.

Duffett M, Chan A, Closs J, McGloin R, McKelvie G, Pong S et al. Stress ulcer prophylaxis in critically ill children: A multicenter observational study. Pediatric Critical Care Medicine. 2020 Feb; 21(2): e107-13. doi: 10.1097/PCC.0000000000002202.

Freitas D, Araújo K, Gonçalves M, do Nascimento GR, Buainain S. Indications of gastric ulcer prophylaxis in hospitalized pediatric patients: an integrative review. Residência Pediátrica. 2021; 11(3). doi: 10.25060/residpediatr-2021.v11n3-230.

Sullivan KM, Dean MA, Soe MM, MCTM M. An introduction to OpenEpi. An Introduction to OpenEpi. 2014.

Mishuk AU. Comprehensive Safety Evaluation of Proton Pump Inhibitors [Doctoral Dissertation]. Auburn University; 2021.

Liu P, McMenamin ÚC, Johnston BT, Murchie P, Iversen L, Lee AJ et al. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. British Journal of Cancer. 2020 Jul; 123(2): 307-15. doi: 10.1038/s41416-020-0860-4.

Pasman EA, Ong B, Witmer CP, Nylund CM. Proton pump inhibitors in children: the good, the bad, and the ugly. Current Allergy and Asthma Reports. 2020 Aug; 20: 1-8. doi: 10.1007/s11882-020-00926-4.

Prabhoo RY, Pai UA, Wadhwa A, Pillai BV, D'souza C, Wadhawan M et al. Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR. Euroasian Journal of Hepato-Gastroenterology. 2024 Jan; 14(1): 99. doi: 10.5005/jp-journals-10018-1430.

Reynolds PM, Wells L, Powell M, MacLaren R. Associated mortality risk of proton pump inhibitor therapy for the prevention of stress ulceration in intensive care unit patients: a systematic review and meta-analysis. Journal of Clinical Gastroenterology. 2023 Jul; 57(6): 586-94. doi: 10.1097/MCG.0000000000001723.

Deliwala SS, Hamid K, Goyal H, Ponnapalli A, Zayed Y, Bala A et al. Proton pump inhibitors versus histamine-2-receptor antagonists for stress ulcer prophylaxis in critically ill patients: a meta-analysis and trial sequential analysis. Journal of Clinical Gastroenterology. 2022 Mar; 56(3): 204-17. doi: 10.1097/MCG.0000000000001562.

Dutta AK, Jain A, Jearth V, Mahajan R, Panigrahi MK, Sharma V et al. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship. Indian Journal of Gastroenterology. 2023 Oct; 42(5): 601-28. doi: 10.1007/s12664-023-01428-7.

Dipasquale V, Cicala G, Spina E, Romano C. A narrative review on efficacy and safety of proton pump inhibitors in children. Frontiers in Pharmacology. 2022 Feb; 13: 839972. doi: 10.3389/fphar.2022.839972.

Alosaily YA, Alfallaj JM, Alabduljabbar JS, Alfehaid EF, Alfayez OM, Elrasheed M. Appropriateness of proton pump inhibitors use in noncritically ill hospitalized children in a tertiary hospital in Saudi Arabia. Saudi Pharmaceutical Journal. 2023 Sep; 31(9): 101723. doi: 10.1016/j.jsps.2023.101723.